Inverse correlation of concurrent BCL2, and C MYC expressions and CD30 positivity as regard the Prognostic significance in diffuse large B-cell lymphoma | ||||
| Benha Medical Journal | ||||
| Article 469, Volume 40, Special issue (Academic), September and October 2023, Page 107-124 PDF (1.13 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bmfj.2023.213074.1829 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
afaf ibrahiem1; Azza Abdel-aziz‎2; Doaa Ghorab3; shimaa yussif4; Nahed Soliman   5
| ||||
| 1pathology departement faculty of medicine mansoura university | ||||
| 2pathology departement, mansoura faculty of medicine | ||||
| 3pathology departement Mansoura faculty of Medicine | ||||
| 4pathology departement mansoura faculty of medicine | ||||
| 5Elrehab villa 43/8 | ||||
| Abstract | ||||
| Background : C MYC, BCL2 and CD30 play an important role in initiation and propagation of diffuse large B-cell lymphoma (DLBCL). Protein expression of these marker were used in the diagnosis, predicting the prognosis and as a therapeutic target in DLBCL purpose: this study aimed to assess the prognostic impact and therapeutic utility of expression patterns of CD30, BCL2, MYC in DLBCL Patients and Methods: This retrospective study was carried out on DLBCL diagnosed at Oncology Centre Mansoura University (2016-2019). The study was approved by IRB of Mansoura faculty of Medicine Code Number: R.23.01.2043, 21/03/2023. Results: BCL2, C MYC, concurrent BCL2,C MYC and CD30 overexpression was present in 76%, 36%,, 26% and 26% of the studied cases respectively. Concurrent expressions of BCL2, C MYC showed significant association with the presence relapse (P= 0.003). concurrent expression of BCL2, C MYC revealed significant association with the progressive therapy response (P=0.003). In addition, C MYC, expression was significantly associated with the presence of exranodal presentation (P=0.03). CD30 protein overexpression was significantly associated with stage II and III (P=0.03). CD30 positivity showed inverse correlation with the concurrent expression of BCL2, C MYC (Correlation Coefficient=--.355, P=0,02). Also CD30 positivity and concurrent expression of BCL2, C MYC reflected significant prognostic impact on overall survival (OS) and disease free survival (DFS) (all P=0.00). Conclusion: concurrent C MYC, BCL2 overexpression is associated with a lower OS, and DFS. CD30 positivity is associated with a better OS, and DFS which can be utilized in management plan of DLBCL. | ||||
| Keywords | ||||
| DLBCL; C MYC; BCL2; CD30; survival. | ||||
|
Statistics Article View: 76 PDF Download: 166 |
||||
